The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The cholesterol that's good for your heart health might be bad for your eye health and vice versa, a new study says.

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...